People.
Performance.
Possibilities.
Driven by
Purpose.
Key Highlights
INR 227,079 Mn
Total Revenues from Operations
INR 54,792 Mn
EBITDA
1,491,740+
Patients Reached through Patient Education Programs
38,974+
Healthcare Professionals Participated in Education and Awareness Programs
26%
Reduction in Scope 1 and Scope 2 Emissions in FY25 from Base Year FY23
R&D
848
Active Patent Applications up
to March 2025
453
ANDAs and NDAs filed with
U.S. FDA up to March 2025
RANKINGS
3rd
In the U.S. (by filled generic prescriptions)
8th
In Indian Pharma Market
12th
Largest Generics Company Globally (by sales)
PRODUCTS
30+
Robust Pipeline of Injectables
20+
Robust Pipeline of Respiratory Products
Leadership Messages
Manju Deshbandhu Gupta
Chairperson's Letter
"Transforming Hope into Healing"
Driven by our commitment to business excellence and innovation, our goal is to be a trusted partner for quality medicines, transforming hope into healing.
READ MORE
Vinita Gupta | Nilesh Gupta
CEO and MD's Letter
"Driven by Purpose"
At Lupin, we are not just manufacturers or marketers of medicines. Our Lupinytts are the catalysts, the agents of change, committed to accelerating, enabling and sparking positive change to the health of patients.
READ MORE
Ramesh Swaminathan
CFO's Letter
"A Year of Excellence"
FY25 was a year of purposeful acceleration, a year where disciplined execution, strategic clarity, and bold investments came together to deliver impressive outcomes.
READ MORE
Assurance Statement